Irish software startup nabs $25M Series C to speed up clinical trials
The startup's platform is meant to digitize and modernize the still largely manually and paper-based process of running and managing clinical trials.
The startup's platform is meant to digitize and modernize the still largely manually and paper-based process of running and managing clinical trials.
The company's initial program, known as ND-1000, is a combination of an existing generic cancer medication with a natural product that is meant to boost the effectiveness of CAR T-Cell therapy.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The financing, led by Thiel's Founders Fund, will help the company expand its reach into Europe and Asia while building up its manufacturing capabilities.